After 3 months, a reassessment allows the doctor to adjust the next protocol based on progress
American Journal of HealthSystem Pharmacy, 62, 173181
In previous clinical trials for obesity, Tesofensine has been studied in varying dosages, typically starting with a lower dose and gradually increasing it to assess efficacy and tolerability during drug administration
For weight loss specifically, oral GLP-1 formulations have been shown in trials to support meaningful weight loss when paired with lifestyle change, but the dose, absorption profile, and daily ritual are different from the injectable version
It is strictly for research purposes only, and human safety is not established
(D) qPCR analysis of GCLC and GCLM gene expression levels of neutrophil mRNA from patients compared to control